Related Experiment Videos
Antitachycardia devices: realities and promises
L S Klein1, W M Miles, D P Zipes
1Krannert Institute of Cardiology, Indianapolis, Indiana 46202-4800.
Journal of the American College of Cardiology
|November 1, 1991
Summary
Implantable cardioverter-defibrillators offer a vital non-drug therapy for ventricular arrhythmias, improving survival rates. Newer devices with enhanced features promise further reductions in mortality for high-risk patients.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- Nonpharmacologic therapy for ventricular arrhythmias is increasingly important.
- Concerns regarding adverse effects of antiarrhythmic drug therapy, highlighted by studies like CAST, underscore the need for alternative treatments.
- The development of implantable cardioverter-defibrillators (ICDs) provides a crucial therapeutic option.
Purpose of the Study:
- To review the features of currently available antitachycardia devices and implantable cardioverter-defibrillators.
- To discuss the features and current implant data of newer antitachycardia devices.
Main Methods:
- Review of existing literature and device specifications.
- Analysis of clinical utility and implant data for current and emerging antitachycardia devices.
Main Results:
- Implantable cardioverter-defibrillators significantly improve survival in patients with life-threatening ventricular arrhythmias and after sudden cardiac arrest.
- Current ICDs offer antitachycardia pacing, bradycardia pacing, cardioversion, and defibrillation capabilities.
- Newer devices with expanded functionalities are expected to further reduce mortality.
Conclusions:
- Implantable cardioverter-defibrillators are a cornerstone in managing ventricular arrhythmias.
- Advancements in ICD technology are enhancing clinical utility and patient outcomes.
- Emerging antitachycardia devices hold promise for even greater reductions in mortality.